These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32157655)

  • 1. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
    Kara M; Tokat F; Pamir MN; Danyeli AE
    Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion.
    Tamura R; Ohara K; Morimoto Y; Kosugi K; Oishi Y; Sato M; Yoshida K; Toda M
    Endocr Pathol; 2019 Jun; 30(2):81-89. PubMed ID: 30903445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
    García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of p16
    Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
    J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
    Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
    Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
    Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
    Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
    Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
    Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
    Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A/p16 inactivation is related to pituitary adenoma type and size.
    Seemann N; Kuhn D; Wrocklage C; Keyvani K; Hackl W; Buchfelder M; Fahlbusch R; Paulus W
    J Pathol; 2001 Apr; 193(4):491-7. PubMed ID: 11276008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
    Asa SL; Mete O; Riddle ND; Perry A
    Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
    Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. scRNA sequencing technology for PitNET studies.
    Asaad W; Utkina M; Shcherbakova A; Popov S; Melnichenko G; Mokrysheva N
    Front Endocrinol (Lausanne); 2024; 15():1414223. PubMed ID: 39114291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic Profiling of Lactotroph Pituitary Neuroendocrine Tumors via RNA Sequencing and Ingenuity Pathway Analysis.
    Hattori Y; Tahara S; Ozawa H; Morita A; Ishii H
    Neuroendocrinology; 2024; 114(7):670-680. PubMed ID: 38643763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
    Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
    J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
    Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
    Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas.
    Vij M; Cho BB; Yokoda RT; Rashidipour O; Umphlett M; Richardson TE; Tsankova NM
    Acta Neuropathol Commun; 2023 May; 11(1):73. PubMed ID: 37138345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience.
    Terry M; Nguyen MP; Tang V; Guney E; Bharani KL; Dahiya S; Choutka O; Borys E; Reis G; Blevins L; Aghi MK; Kunwar S; DeGroot J; Raleigh DR; Pekmezci M; Bollen AW; Cha S; Joseph NM; Perry A
    Endocr Pathol; 2024 Dec; 35(4):338-348. PubMed ID: 39388031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.